Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).

27 Oct 2010

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

Researchers discover gene that contributes to depression

Yale University researchers have found a gene that seems to be a key contributor to the onset of depression and is a promising target for a new class of antidepressants, they report Oct. 17 in the journal Nature Medicine.

18 Oct 2010

AstraZeneca launches new campaign on depression through Facebook and Twitter

AstraZeneca is launching a new campaign called "Take on Depression" through a "Take on Depression" Facebook page and a @FaceDepression Twitter feed to support, educate, and inspire those affected by bipolar depression and major depressive disorder (MDD), also known as depression.

15 Oct 2010

Fisher Wallace Laboratories launches easy-to-use medical device for depression treatment

Fisher Wallace Laboratories today announced the launch of a bold YouTube video campaign that challenges the pharmaceutical drug industry and introduces the company's easy-to-use medical device prescribed for the self-treatment of depression: the Fisher Wallace Cranial Stimulator.

6 Oct 2010

Researchers to conduct trial to improve drug abstinence, relapse rates

A $15.7 million award from the National Institute on Drug Abuse (NIDA) is allowing researchers to see whether consistent exercise will help people abstain from stimulant abuse.

6 Oct 2010

Supplemental brief dynamic therapy does not benefit patients with obsessive-compulsive disorder: Study

This study demonstrates that supplemental brief dynamic therapy in the treatment of patients with obsessive compulsive-disorder with concurrent major depressive disorder (who are receiving effective medication) has no significant clinical effect on both obsessive and depressive symptoms.

5 Oct 2010

Study finds children with ADHD have high risk for adolescent depression

Young children with attention-deficit/hyperactivity disorder (ADHD) appear to be at greater risk for adolescent depression and/or suicide attempts five to 13 years after diagnosis, according to a report in the October issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

5 Oct 2010

Depressed pregnant women at increased risk of delivering preterm birth and low-birth weight infants

Clinical depression puts pregnant women at increased risk of delivering prematurely and of giving birth to below-normal weight infants, according to a report published Oct. 4 in the Archives of General Psychiatry.

5 Oct 2010

Reduced levels of brain-derived neurotrophic factor are a trait marker for psychogenic non-epileptic seizures

New research from Rhode Island Hospital found that reduced levels of brain-derived neurotrophic factor (BDNF), a protein in the brain that encourages growth of neurons, may be a trait marker for individuals with psychogenic non-epileptic seizures (PNES) (seizures that are psychological in origin). The findings are published in the October 4, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

5 Oct 2010

Depression treatment guidelines updated

There has been an update in the treatment of clinical depression. This includes suggestions on the use of medication, talk therapy, exercise, and alternative treatments and puts more emphasis on tailor made treatments for patients.

4 Oct 2010

VIVUS announces QNEXA study results for obesity treatment

VIVUS, Inc. today announced positive top-line results from a two-year study of QNEXA(phentermine/topiramate) Controlled Release Capsules, an investigational therapy for treatment of obesity, a condition that affects approximately one-third of adult Americans.

21 Sep 2010

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode.

15 Sep 2010

Heart patients with Type D personality at higher risk of future cardiovascular problems

Heart patients with the "distressed" (Type D) personality profile may face a higher risk of future cardiovascular problems, according to a summary article published in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

15 Sep 2010

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

7 Sep 2010

SAMe dietary supplement effective for major depressive disorders: Study

A new study conducted by investigators at Harvard Medical School and Massachusetts General Hospital (MGH) suggests that S-Adenosyl Methionine (SAMe), an over-the-counter dietary supplement, can be an effective, relatively well-tolerated, adjunctive treatment for adults with major depressive disorders who do not respond to their treatment with antidepressant medication.

2 Sep 2010

23rd ECNP Press conference on impact of circadian rhythms on human brain

All humans are synchronised to the rhythmic light-dark changes that occur on a daily basis. Rhythms in physiological and biochemical processes and behavioural patterns persist in the absence of all external 24-hour signals from the physical environment, with a period that is close to 24 hours

30 Aug 2010

Mental health issues during pregnancy contribute to infant mortality and poor child health

Clinical depression and anxiety during pregnancy results in smaller babies that are more likely to die in infancy, according to new research published in the open access journal BMC Public Health. The study, which focused on women living in rural Bangladesh, provides the first finding of its kind in a non-Western population. The research indicates that mental health issues are likely to be a primary contributor to infant mortality and poor child health, above poverty, malnutrition or low socio-economic status.

26 Aug 2010

USFDA approves Sun Pharma's generic Venlafaxine Hydrochloride Extended Release tablets ANDA

Sun Pharma announced that USFDA has granted an approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Venlafaxine Hydrochloride Extended Release tablets.

19 Aug 2010

Depressive Cognition Scale questions can detect cognitive symptoms of early depression

A diagnostic test of eight short questions designed by Jaclene Zauszniewski from the Frances Payne Bolton School of Nursing at Case Western Reserve University can be used to detect depressive thinking patterns that lead to clinical depression in women who care for an adult family member with a serious mental illness.

17 Aug 2010

Major Depressive Disorder News and Research

Further Reading

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Researchers discover gene that contributes to depression

AstraZeneca launches new campaign on depression through Facebook and Twitter

Fisher Wallace Laboratories launches easy-to-use medical device for depression treatment

Researchers to conduct trial to improve drug abstinence, relapse rates

Supplemental brief dynamic therapy does not benefit patients with obsessive-compulsive disorder: Study

Study finds children with ADHD have high risk for adolescent depression

Depressed pregnant women at increased risk of delivering preterm birth and low-birth weight infants

Reduced levels of brain-derived neurotrophic factor are a trait marker for psychogenic non-epileptic seizures

Depression treatment guidelines updated

VIVUS announces QNEXA study results for obesity treatment

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

Heart patients with Type D personality at higher risk of future cardiovascular problems

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

SAMe dietary supplement effective for major depressive disorders: Study

23rd ECNP Press conference on impact of circadian rhythms on human brain

Mental health issues during pregnancy contribute to infant mortality and poor child health

USFDA approves Sun Pharma's generic Venlafaxine Hydrochloride Extended Release tablets ANDA

Depressive Cognition Scale questions can detect cognitive symptoms of early depression

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News